InvestorsHub Logo
Followers 55
Posts 2608
Boards Moderated 0
Alias Born 02/04/2014

Re: thenewmixer post# 31501

Thursday, 02/05/2015 1:41:05 PM

Thursday, February 05, 2015 1:41:05 PM

Post# of 144814
I am providing evidence for people to discern for themselves and I will provide it again as there is no intent on my part to mislead anyone.

AustriaNova conducted trials years ago but went bankrupt and was unable to compete them. We bought exclusive rights for CiaB' use for oncology and diabetes.

Austrianova's trials beat the gold standard in those trials. In recent studies we also did well against the current standard ovarian cancer in testing for malignant ascites... and are now starting a 13 treatment extended study with TD2 in preparation for clinical trials.

And all bios "play around" with mice as you put it. This must be done before human trials and is called a clinical study. Understanding how bios work will help with some of the confusion here.

http://www.mdpi.com/1999-4923/6/3/

http://www.genetherapy.me/cell-therapy/nuvilex-announces-preliminary-data-from-preclinical-study-of-effects-of-its-pancreatic-cancer-treatment-on-ascites.php

http://www.nasdaq.com/press-release/pharmacyte-biotechs-expanded-followup-study-on-malignant-ascites-fluid-accumulation-in-final-stage-20150126-00537

http://www.sec.gov/Archives/edgar/data/1157075/000115707513000007/a3rdfaddnvlx2013.htm

http://www.nuvilex.com/latest-news/24-nuvilex-inc-restructures-corporate-operations-to-reflect-biotechnology-focus
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PMCB News